Deutsche Bank Upgrades Coupang to Buy, Strong Regulatory Resilience
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Source: CNBC
- Rating Upgrade: Deutsche Bank upgraded Coupang from hold to buy, citing the company's strong resilience against regulatory scrutiny, particularly after facing a record antitrust fine in June 2024, which has not diminished its market position.
- Biotech Outlook: Goldman Sachs upgraded BioNTech from neutral to buy, highlighting the company's strategic suite of oncology programs targeting a potential market exceeding $100 billion, with key data expected to unlock in 2026, positioning it for leadership in emerging product cycles.
- Market Challenges: Barclays downgraded HP from equal weight to underweight, noting that the company faces significant long-term challenges in both PCs and printing, which will likely keep the stock under pressure in 2026 despite its current inexpensive valuation and lack of catalysts.
- EV Market Positioning: Macquarie upgraded Nio from market perform to outperform, asserting that the company is well-positioned to navigate the current headwinds in the Chinese electric vehicle market, thereby maintaining its competitive edge.
Analyst Views on BNTX
Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 141.93 USD with a low forecast of 116.00 USD and a high forecast of 181.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
12 Buy
3 Hold
0 Sell
Strong Buy
Current: 106.070
Low
116.00
Averages
141.93
High
181.00
Current: 106.070
Low
116.00
Averages
141.93
High
181.00
About BNTX
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
